Form 4: Neurocrine Biosciences Director Acquires Stock Options
SEC Form 4 Filing
Kevin Charles Gorman, a director at Neurocrine Biosciences, acquired 6,610 non-qualified stock options on May 21, 2025, at a price of $0.
Summary
- Kevin Charles Gorman, a director of Neurocrine Biosciences Inc. (NBIX), reported a transaction involving the acquisition of derivative securities.
- On May 21, 2025, Gorman acquired 6,610 non-qualified stock options with an exercise price of $120.56.
- These options vest in 12 monthly installments starting June 21, 2025, and expire on May 21, 2035.
- Following the transaction, Gorman directly owns 6,610 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own. It reflects standard executive compensation practices.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests a continued involvement and interest of the director in the company's performance over the next year.
Industry Context
This is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency into the actions of company directors and officers.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in the biotechnology industry, used to align the interests of management with those of shareholders.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their compensation packages.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of the transaction: acquisition of stock options. |
| 06/21/2025 | Vesting start date for the acquired stock options. |
| 05/21/2035 | Expiration date of the acquired stock options. |
| 05/22/2025 | Date of the form filing. |
Keywords
stock options, derivative securities, Form 4, Neurocrine Biosciences, NBIX, director, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.